1. Home
  2. FSP vs IPHA Comparison

FSP vs IPHA Comparison

Compare FSP & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Street Properties Corp.

FSP

Franklin Street Properties Corp.

N/A

Current Price

$0.34

Market Cap

33.3M

Sector

Real Estate

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.75

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FSP
IPHA
Founded
1981
1999
Country
United States
France
Employees
28
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.3M
165.3M
IPO Year
2001
2014

Fundamental Metrics

Financial Performance
Metric
FSP
IPHA
Price
$0.34
$1.75
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $5.75
AVG Volume (30 Days)
★ 887.2K
37.5K
Earning Date
04-28-2026
03-26-2026
Dividend Yield
★ 6.34%
N/A
EPS Growth
★ 15.69
N/A
EPS
N/A
★ N/A
Revenue
★ $107,162,000.00
N/A
Revenue This Year
$17.91
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.32
$1.18
52 Week High
$1.70
$2.71

Technical Indicators

Market Signals
Indicator
FSP
IPHA
Relative Strength Index (RSI) 41.18 33.84
Support Level $0.32 $1.67
Resistance Level $0.41 $1.83
Average True Range (ATR) 0.02 0.10
MACD 0.00 -0.03
Stochastic Oscillator 30.70 11.85

Price Performance

Historical Comparison
FSP
IPHA

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: